Daily Trade

While it’s always risky to go against the masses, certain short-squeeze stocks for contrarians to consider may perform surprisingly well. Invariably, even the collective sometimes gets things wrong. Certainly, if everyone bets on the same horse, the subsequent individual reward (if any) would be significantly limited. And that’s part of the reason why going against

Taiwan Semiconductor Manufacturing Co. said Thursday that fourth-quarter net profit rose to a new record thanks to growing demand for high-speed computing and better margins. The world’s largest contract chip maker 2330, +0.41% TSM, +0.63% said net profit for the quarter ended Dec. 31 rose 78% from a year earlier to 295.90 billion Taiwan dollars

In 2022, I was able to greatly reduce my stock portfolio’s losses by shorting several U.S. equities. I found it fairly easy to find favorable stocks to short, as the valuations of many companies were ridiculously high last year, and many stocks were pricing in scenarios that almost certainly would never materialize. For example, I

Not only is the ground in the San Francisco Bay Area saturated, but so is the cloud market pioneered by Salesforce Inc. and on top of margin pressure and lower quality earnings, one analyst downgraded the stock of the customer-relations management software giant. On Wednesday, Bernstein analyst Stacy Rasgon downgraded Salesforce CRM, -0.95% to underperform

Shares in SoFi Technologies (NASDAQ:SOFI) have traded sideways over the past month. This is not surprising, given there have not been too many headlines about SOFI stock, since the short-lived excitement surrounding news of insider buying by CEO Anthony Noto. That said, there is something on the horizon that will likely bring this fintech stock

Tesla Inc. has applied for a nearly billion-dollar expansion of its Austin, Texas, gigafactory. According to filings dated this week with the Texas Department of Licensing and Registration, Tesla is planning an investment of roughly $717 million to add about 1.4 million square feet of space at the auto factory, for a total of about

If you have a love-hate relationship with Mullen Technologies (NASDAQ:MULN), you’re not alone. “Bought at [41 cents] and I know it’s going to crash,” read a post on Reddit last week. “I’m about to get burned I know it.” The electric vehicle penny stock has become a curiosity over the past several months, earning both

Americans can still order more free COVID-19 test kits from the federal government. The Biden administration is mailing out four more rapid at-home COVID tests per household. You can order them online via the United States Postal Service at special.usps.com/testkits or by calling 1-800-232-0233. You can also visit covid.gov/tests to request the free testing kits — it’s

In 2012, Tesla (NASDAQ:TSLA) launched its first mass-production vehicle, the Tesla Model S. Love or hate the firm (or its controversial boss), the vehicle was a stunning leap forward in electric vehicle technology. The car could travel 265 miles on a single charge and earned the 2013 Motor Trend Car of the Year award. Reviewers

By Bingyan Wang Shares of BYD Co., the Chinese rival to Tesla, fell Tuesday after Warren Buffett further trimmed his holding in the company. The listed Chinese electric vehicle maker slid as much as 2.9% in morning trade in Hong Kong, while the benchmark Hang Seng Index was 0.4% lower. BYD’s shares in Shenzhen dropped

For investors in a wide swath of companies, 2022 was a rough year. That said, it was a downright brutal year for those invested in most tech companies. Indeed, the three stocks on this list are among the mega-cap juggernauts of the tech world. With market capitalizations ranging from $335 billion to more than $2

Dear Tax Guy, We gave our daughter money towards a down payment on a home and learned we had to file a gift tax return. Our accountant charged us $486 for this. Why can’t you just add a form to your regular tax return? What is so complicated that it would cost so much? Sticker

By Bingyan Wang Shares of Alibaba Group Holdings are higher following news that co-founder Jack Ma is ceding control of affiliate company Ant Group Co., potentially paving the way to revive plans for an initial public offering by the fintech giant. Alibaba’s Hong Kong-listed shares advanced as much as 8.3% in early trade Monday, widening

Dear Quentin, I’ll keep this short, as I don’t take any pleasure in reliving it. I have corresponded with a man for two months on a dating site that shall remain nameless (except to say it starts with T and ends in R). He had a very strong and decisive personality, which I liked, and

After a bruising 2022, how will electric vehicle (EV) manufacturer Lucid Group (NASDAQ:LCID) treat its loyal investors during the next 12 months? It’s hard to envision a strong bull case for LCID stock as there no clear positive catalysts. Lucid did raise capital recently, but it wasn’t “free money” by any means. Moreover, the automaker’s

Dear Quentin, I bought my home in California for $520,000 in 2017. It’s now worth $980,000. In 2019, I met my now-wife who moved in at the beginning of 2020. We married six months later in July 2020. Things were going great and we decided to have one bank account. I also added my wife

Meta Materials (NASDAQ:MMAT) stock was a popular meme play during 2021, falling off the radar of the investing public as the “meme craze” came to a close. However, in recent months, MMAT stock has again been making headlines in both a bad way and, more recently, in a good way. In December, the materials technology company

Dear MarketWatch, My husband and I bought a second home two years ago, for $160,000, with a 30-year mortgage at 2.5%. We bought it with the sole purpose of renting it out to our son and his new wife.  They were recent college graduates, and just starting their careers. They’ve made this house their home.

Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof. With growing demand for gene therapies, immune oncology, and precision medicine, biotech companies have a unique opportunity to impact the world

AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone payments to partners. AbbVie ABBV, +1.87% said it must pay out $243 million in milestone payments to partners for acquired in-process research and development, or